Gamco Investors INC. ET AL Has $2.22 Million Stock Position in Evolent Health, Inc. (NYSE:EVH)

Gamco Investors INC. ET AL increased its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 43.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,100 shares of the technology company's stock after buying an additional 60,000 shares during the period. Gamco Investors INC. ET AL owned 0.17% of Evolent Health worth $2,217,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Summit Creek Advisors LLC grew its stake in Evolent Health by 0.8% in the fourth quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company's stock valued at $2,274,000 after acquiring an additional 1,636 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Evolent Health in the 4th quarter worth $26,000. Parkside Financial Bank & Trust grew its position in Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after purchasing an additional 2,358 shares during the period. Johnson Investment Counsel Inc. increased its stake in Evolent Health by 28.0% during the 4th quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company's stock valued at $131,000 after purchasing an additional 2,542 shares in the last quarter. Finally, R Squared Ltd acquired a new position in Evolent Health during the fourth quarter worth $31,000.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $8.95 on Friday. The company has a market capitalization of $1.04 billion, a P/E ratio of -10.92 and a beta of 1.20. The company's 50-day moving average is $9.66 and its 200 day moving average is $13.41. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a fifty-two week low of $8.35 and a fifty-two week high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The company had revenue of $646.54 million during the quarter, compared to analysts' expectations of $650.92 million. On average, equities research analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Insider Activity at Evolent Health

In other Evolent Health news, Director Brendan B. Springstubb bought 5,000 shares of Evolent Health stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the completion of the purchase, the director now directly owns 11,842 shares of the company's stock, valued at approximately $103,617.50. This trade represents a 73.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Daniel Joseph Mccarthy purchased 11,040 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the purchase, the president now directly owns 389,004 shares in the company, valued at $3,504,926.04. This represents a 2.92 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 74,000 shares of company stock worth $666,315. Insiders own 1.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Truist Financial reduced their price objective on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Stephens decreased their price objective on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday, January 21st. Canaccord Genuity Group lowered their price objective on Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Oppenheimer cut their target price on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Friday, February 21st. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Evolent Health has an average rating of "Buy" and an average target price of $17.64.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE:EVH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.